Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
暂无分享,去创建一个
J. H. Kim | Jeong‐Hoon Lee | Y. Seo | J. Jang | M. Kim | D. Y. Kim | Sangyoun Hwang | S. Cho | E. Jang | Hyung Joon Kim | Y. Jung | K. Yoon | H. Yim | H. W. Lee | Y. Hong | Young-Sun Lee | B. K. Jang | Sang-Youn Hwang
[1] Do Young Kim,et al. Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma , 2020, Clinical and molecular hepatology.
[2] Jun Kato,et al. Switching to systemic therapy after locoregional treatment failure: Definition and best timing , 2020, Clinical and molecular hepatology.
[3] F. Piscaglia,et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. , 2019, Journal of hepatology.
[4] M. Kudo,et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) , 2019, Annals of Oncology.
[5] Kehua Zhou,et al. Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma , 2019, Cancers.
[6] M. Kudo,et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). , 2019, Journal of Clinical Oncology.
[7] M. Kudo. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances , 2018, Cancers.
[8] I. Grivicich,et al. Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience , 2018, Digestive Diseases.
[9] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[10] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[11] M. Kudo,et al. Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib , 2018, Zeitschrift für Gastroenterologie.
[12] Joong-Won Park,et al. Epidemiology of liver cancer in South Korea , 2017, Clinical and molecular hepatology.
[13] Alan D. Lopez,et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.
[14] F. Camacho,et al. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. , 2015, The oncologist.
[15] O. Yokosuka,et al. Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors , 2015, Investigational New Drugs.
[16] G. Spolverato,et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. , 2015, Journal of hepatology.
[17] S. Ye,et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Bang,et al. Non–Laboratory-Based Self-Assessment Screening Score for Non-Alcoholic Fatty Liver Disease: Development, Validation and Comparison with Other Scores , 2014, PloS one.
[19] M. Brose,et al. Management of sorafenib-related adverse events: a clinician's perspective. , 2014, Seminars in oncology.
[20] L. Jeng,et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Y. Paik,et al. Clinical parameters predictive of outcomes in sorafenib‐treated patients with advanced hepatocellular carcinoma , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[22] P. Elias,et al. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression , 2012, The Journal of investigative dermatology.
[23] M. Kudo,et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. , 2011, European journal of cancer.
[24] Z. Wu,et al. Meta‐analysis of dermatological toxicities associated with sorafenib , 2011, Clinical and experimental dermatology.
[25] M. Yoshikawa,et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma , 2011, Hepatology international.
[26] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[27] H. Kong,et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. , 2008, The oncologist.
[28] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[29] M. Lacouture,et al. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis , 2008, Acta oncologica.
[30] B. Goldspiel,et al. Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer , 2007, Pharmacotherapy.
[31] E. Proksch,et al. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. , 1996, Acta dermato-venereologica.
[32] S. Kaasa,et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. , 1994, European journal of cancer.